Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
While some say this strategy's failure rate is "too high," it's one step closer to the "white grail" of a shorter 24-week formula.
Read Full NewsA retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.
For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.
Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.
Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.
1.
CD39 Blockade Shows Potential in Early-Stage Lung Cancer
2.
In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.
3.
Long-Term CAR-T Results in Lymphoma Confirm Early Promise
4.
In KRAS-mutated non-small cell lung cancer, glecirasib exhibits promising efficacy.
5.
"We Caught It Early": Advantage or Disadvantage?
1.
Practical Standards in Hematology for Healthcare Excellence
2.
Cancer Susceptibility Landscapes in Precision Oncology
3.
The importance of understanding normal serum osmolality
4.
Unraveling the Mysteries of Hematocrit: How It Impacts Your Health
5.
Understanding QSOFA: A Vital Tool for Recognizing Sepsis
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
2.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
4.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge